Across North America, the increasing focus on early disease detection, chronic condition management, and preventive healthcare is driving the use of inflammation biomarkers. CRP testing supports clinical evaluation across multiple therapeutic areas and can be efficiently incorporated into automated laboratory workflows. The presence of well-established diagnostic networks, advanced healthcare facilities, and widespread access to laboratory services strengthens regional adoption. Growing demand for cardiovascular risk assessment and routine monitoring of inflammatory conditions is also contributing to sustained utilization of CRP testing across North American healthcare settings.

Market Overview

The C-Reactive Protein Testing Market was valued at US$ 6.08 billion in 2025 and is projected to reach US$ 6.75 billion by 2034, registering a CAGR of 1.32% during 2026–2034. Demand is expected to remain stable as healthcare providers increasingly incorporate inflammatory biomarkers into routine diagnostics, chronic disease monitoring, cardiovascular risk assessment, and treatment follow-up. North America accounted for approximately 38–40% of the market in 2025, while Asia Pacific is positioned for comparatively faster growth through expanding healthcare infrastructure and laboratory modernization.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00006954

Market Demand: Expanding Clinical Applications

C-Reactive Protein Testing Market Demand Growth is being supported by the expanding use of CRP as a nonspecific indicator of inflammation across multiple clinical settings. Hospitals and reference laboratories continue to generate substantial testing volumes for infection assessment, inflammatory disorders, cardiovascular evaluation, and patient monitoring. The increasing prevalence of chronic diseases also contributes to recurring testing requirements, particularly among patients requiring long-term follow-up. Conventional CRP remains important in acute care, while high-sensitivity CRP is gaining attention in preventive cardiology and cardiometabolic risk assessment. These applications create a broad and relatively resilient demand base despite the mature nature of CRP diagnostics.

Market Trends: Laboratory Automation Accelerates Adoption

Laboratory automation is one of the most significant trends shaping demand. Immunoturbidimetric assays remain the largest assay format because they can be efficiently integrated with automated clinical chemistry analyzers and high-throughput laboratory workflows. Automation enables laboratories to process larger sample volumes with reduced manual intervention, improved turnaround times, and greater consistency. Diagnostic providers are increasingly seeking platforms that combine CRP with other inflammatory, cardiac, metabolic, and infectious biomarkers. This menu consolidation enables laboratories to improve operational efficiency while manufacturers strengthen customer retention through integrated analyzer and reagent ecosystems. The trend is particularly relevant for large hospitals and centralized reference laboratories.

Market Trends: Growing Role of High-Sensitivity CRP

High-sensitivity C-reactive protein, or hs-CRP, is emerging as an important area of opportunity because it can identify low-grade inflammation relevant to selected cardiovascular risk assessment applications. The segment accounted for approximately 31–33% of the market in 2025 and is expected to grow at a CAGR of 1.1–1.5% through 2034. Its increasing integration into preventive cardiology, wellness screening, and cardiometabolic evaluation is creating additional testing opportunities. Although hs-CRP does not replace established cardiovascular assessments, it can provide complementary information when interpreted alongside lipid profiles, glucose levels, blood pressure, lifestyle factors, and clinical history.

Growth Analysis: Chronic Disease Monitoring Supports Recurring Testing

The rising need for chronic disease monitoring represents a significant factor supporting demand. CRP testing is used alongside clinical evaluation to monitor inflammatory activity in rheumatoid arthritis, inflammatory bowel disease, and other chronic conditions. It can also provide supplementary information in selected oncology and endometriosis-related clinical and research workflows. Recurring testing among patients undergoing long-term disease management helps maintain laboratory volumes. As healthcare systems increasingly emphasize preventive care and longitudinal disease monitoring, diagnostic laboratories can benefit from consistent demand for inflammatory biomarkers. This recurring utilization provides stability to manufacturers of reagents, calibrators, controls, and analyzer platforms.

Regional Outlook: North America Maintains a Leading Position

North America remains the leading regional contributor, accounting for approximately 38–40% of demand in 2025. The US represents the dominant share of the regional market, supported by extensive reference laboratory networks, integrated healthcare systems, high outpatient testing volumes, and widespread use of automated clinical chemistry analyzers. Preventive healthcare programs and cardiovascular risk evaluation also contribute to the adoption of hs-CRP. Canada benefits from public laboratory services and preventive healthcare pathways, while Mexico is supported by expanding private healthcare infrastructure. Growth across the region is expected to remain moderate because CRP testing is already well established within routine diagnostic workflows.

Regional Outlook: Asia Pacific Offers Emerging Opportunities

Asia Pacific held approximately 22–24% of the market in 2025 and is expected to register a CAGR of 1.2–1.6% during 2026–2034, making it one of the faster-growing regional markets. China benefits from expanding hospital infrastructure and increasing demand for infection diagnostics and preventive cardiovascular screening. Japan and South Korea have established laboratory automation capabilities, while India is experiencing increasing demand through private diagnostic networks and tertiary care hospitals. Healthcare infrastructure investments, growing insurance coverage, laboratory modernization, and increasing access to diagnostic services in secondary cities are expected to support future demand.

Segmentation Trends: Assay Type and End Use

Immunoturbidimetric assays accounted for approximately 43–45% of the market in 2025, making them the largest assay category. Their compatibility with automated chemistry systems and suitability for high-throughput testing support continued adoption. ELISA remains relevant for research, specialized diagnostics, and biomarker validation, while chemiluminescence immunoassays support sensitive testing in advanced laboratories. By end use, hospitals and laboratories remain major contributors because of their high testing volumes and sophisticated infrastructure. Clinics are also gaining importance as decentralized and rapid testing becomes increasingly relevant for inflammation assessment, infection triage, and chronic disease monitoring.

Future Trends: Decentralized and Digitally Connected Testing

Future innovation is expected to focus on decentralized testing, connectivity, and advanced biomarker monitoring. Compact CRP analyzers can help primary care providers obtain rapid inflammatory information and support decisions related to referral, infection evaluation, and patient follow-up. At the same time, research into biosensors, microneedle sampling, and near-patient technologies could eventually expand inflammatory biomarker monitoring beyond conventional laboratory settings. Digital connectivity may further enable test results to move directly into laboratory information systems and electronic health records. These developments could improve workflow efficiency while creating opportunities for manufacturers offering integrated testing, quality control, and data-management solutions.

Competitive Landscape: Leading Companies

• Abcam Limited

• Bio-Techne Corporation

• F. Hoffmann-La Roche Ltd

• Randox Laboratories Ltd.

• Merck KGaA

• Thermo Fisher Scientific Inc.

• LifeSpan BioSciences, Inc.

• Abaxis, Inc.

• Quest Diagnostics Incorporated

• Abbott Laboratories

• Siemens Healthineers AG

Strategic Outlook: Focus on Efficiency and Standardization

The outlook remains centered on volume-led growth, laboratory efficiency, and standardization rather than aggressive capacity expansion. Suppliers can strengthen their position by offering validated assays, reliable reagents, calibration materials, quality controls, and integrated laboratory solutions. Emerging healthcare systems also present opportunities as laboratories transition from fragmented testing processes toward standardized automated platforms. India, China, Gulf countries, and selected African markets offer potential as healthcare infrastructure expands and diagnostic providers increasingly prioritize quality and international laboratory standards. These developments are expected to create incremental opportunities for suppliers that can combine product reliability with technical support and scalable distribution.

Related Reports

Laboratory Animal Diets Market Growth & Forecast 2034

Anti-Ageing Drugs Market Growth, Share & Trends by 2034

About US

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us

Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish